Contemporary report of surgical outcomes after single‐stage total pancreatectomy: A 10‐year experience

Nitzan Zohar,Luke Kowal,David Moskal,Francesca Ponzini,George Sun,Ryan J. Lamm,John Williamson,Avinoam Nevler,Harish Lavu,Warren R. Maley,Charles J. Yeo,Wilbur B. Bowne
DOI: https://doi.org/10.1002/jso.27614
2024-02-29
Journal of Surgical Oncology
Abstract:Background Surgeons rarely perform elective total pancreatectomy (TP). Our study seeks to report surgical outcomes in a contemporary series of single‐stage (SS) TP patients. Methods Between the years 2013 to 2023 we conducted a retrospective review of 60 consecutive patients who underwent SSTP. Demographics, pathology, treatment‐related variables, and survival were recorded and analyzed. Results SSTP consisted of 3% (60/1859) of elective pancreas resections conducted. Patient median age was 68 years. Ninety percent of these patients (n = 54) underwent SSTP for pancreatic ductal adenocarcinoma (PDAC). Conversion from a planned partial pancreatectomy to TP occurred intraoperatively in 31 (52%) patients. Fifty‐nine patients (98%) underwent an R0 resection. Median length of hospital stay was 6 days. The majority of morbidities were minor, with 27% patients (n = 16) developing severe complications (Clavien‐Dindo ≥3). Thirty and ninety‐day mortality rates were 1.67% (one patient) and 5% (three patients), respectively. Median survival for the entire cohort was 24.4 months; 22.7 months for PDAC patients, with 1‐, 3‐, and 5‐year survival of 68%, 43%, and 16%, respectively. No mortality occurred in non‐PDAC patients (n = 6). Conclusion Elective single‐stage total pancreatectomy can be a safe and appropriate treatment option. SSTP should be in the armamentarium of surgeons performing pancreatic resection.
oncology,surgery
What problem does this paper attempt to address?